Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K+ (K2P) channels
Class IC antiarrhythmic drugs are commonly used for rhythm control in atrial fibrillation. In addition, class I drugs are administered to suppress ventricular tachyarrhythmia in selected cases. The multichannel blocking profile of class I compounds includes reduction of cardiac potassium currents in...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
23 September 2013
|
| In: |
European journal of pharmacology
Year: 2013, Volume: 721, Issue: 1/3, Pages: 237-248 |
| ISSN: | 1879-0712 |
| DOI: | 10.1016/j.ejphar.2013.09.029 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ejphar.2013.09.029 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0014299913006821 
|
| Author Notes: | Constanze Schmidt, Felix Wiedmann, Patrick A. Schweizer, Rüdiger Becker, Hugo A. Katus, Dierk Thomas |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 176186078X | ||
| 003 | DE-627 | ||
| 005 | 20230426093854.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210705s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejphar.2013.09.029 |2 doi | |
| 035 | |a (DE-627)176186078X | ||
| 035 | |a (DE-599)KXP176186078X | ||
| 035 | |a (OCoLC)1341418160 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schmidt, Constanze |e VerfasserIn |0 (DE-588)1055852174 |0 (DE-627)792733142 |0 (DE-576)411903721 |4 aut | |
| 245 | 1 | 0 | |a Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K+ (K2P) channels |c Constanze Schmidt, Felix Wiedmann, Patrick A. Schweizer, Rüdiger Becker, Hugo A. Katus, Dierk Thomas |
| 246 | 3 | 3 | |a Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K + (K 2P) channels |
| 246 | 3 | 3 | |a Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K plus (K 2P) channels |
| 264 | 1 | |c 23 September 2013 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Im Titel ist "+" hochgestellt, "2P" tiefgestellt | ||
| 500 | |a Gesehen am 05.07.2021 | ||
| 520 | |a Class IC antiarrhythmic drugs are commonly used for rhythm control in atrial fibrillation. In addition, class I drugs are administered to suppress ventricular tachyarrhythmia in selected cases. The multichannel blocking profile of class I compounds includes reduction of cardiac potassium currents in addition to their primary mechanism of action, sodium channel inhibition. Blockade of two-pore-domain potassium (K2P) channels in the heart causes action potential prolongation and may provide antiarrhythmic action in atrial fibrillation. This study was designed to elucidate inhibitory effects of class I antiarrhythmic drugs on K2P channels. Human K2P2.1 (TREK1) and hK2P3.1 (TASK1) channels were systematically tested for their sensitivity to clinically relevant class IA (ajmaline), class IB (mexiletine), and class IC (propafenone) antiarrhythmic compounds using whole-cell patch clamp and two-electrode voltage clamp electrophysiology in Chinese hamster ovary cells and in Xenopus oocytes. Mexiletine and propafenone inhibited hK2P2.1 (IC50,mexiletine=173µM; IC50,propafenone=7.6µM) and hK2P3.1 channels (IC50,mexiletine=97.3µM; IC50,propafenone=5.1µM) in mammalian cells. Ajmaline did not significantly reduce current amplitudes. K2P channels were blocked in open and closed states, resulting in resting membrane potential depolarization. Open rectification properties of the channels were not affected by class I drugs. In summary, class I antiarrhythmic drugs target cardiac K2P K+ channels. Blockade of hK2P2.1 and hK2P3.1 potassium currents provides mechanistic evidence to establish cardiac K2P channels as antiarrhythmic drug targets. | ||
| 650 | 4 | |a Ajmaline | |
| 650 | 4 | |a Antiarrhythmic drug | |
| 650 | 4 | |a Cardiac arrhythmia | |
| 650 | 4 | |a Cellular excitability | |
| 650 | 4 | |a K channel | |
| 650 | 4 | |a Membrane potential | |
| 650 | 4 | |a Mexiletine | |
| 650 | 4 | |a Propafenone | |
| 700 | 1 | |a Wiedmann, Felix Tobias |d 1987- |e VerfasserIn |0 (DE-588)1055852441 |0 (DE-627)792733479 |0 (DE-576)411904159 |4 aut | |
| 700 | 1 | |a Schweizer, Patrick Alexander |d 1976- |e VerfasserIn |0 (DE-588)129886254 |0 (DE-627)48277987X |0 (DE-576)297887130 |4 aut | |
| 700 | 1 | |a Becker, Rüdiger |e VerfasserIn |0 (DE-588)1032502541 |0 (DE-627)738501409 |0 (DE-576)380071061 |4 aut | |
| 700 | 1 | |a Katus, Hugo |d 1951- |e VerfasserIn |0 (DE-588)108916618 |0 (DE-627)577155040 |0 (DE-576)289625076 |4 aut | |
| 700 | 1 | |a Thomas, Dierk |d 1974- |e VerfasserIn |0 (DE-588)123896258 |0 (DE-627)706465601 |0 (DE-576)29393164X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of pharmacology |d New York, NY [u.a.] : Elsevier, 1967 |g 721(2013), 1/3, Seite 237-248 |h Online-Ressource |w (DE-627)300897340 |w (DE-600)1483526-5 |w (DE-576)081952627 |x 1879-0712 |7 nnas |a Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K+ (K2P) channels |
| 773 | 1 | 8 | |g volume:721 |g year:2013 |g number:1/3 |g pages:237-248 |g extent:12 |a Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K+ (K2P) channels |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejphar.2013.09.029 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0014299913006821 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210705 | ||
| 993 | |a Article | ||
| 994 | |a 2013 | ||
| 998 | |g 123896258 |a Thomas, Dierk |m 123896258:Thomas, Dierk |d 910000 |d 910100 |d 50000 |e 910000PT123896258 |e 910100PT123896258 |e 50000PT123896258 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 6 |y j | ||
| 998 | |g 108916618 |a Katus, Hugo |m 108916618:Katus, Hugo |d 910000 |d 910100 |e 910000PK108916618 |e 910100PK108916618 |k 0/910000/ |k 1/910000/910100/ |p 5 | ||
| 998 | |g 1032502541 |a Becker, Rüdiger |m 1032502541:Becker, Rüdiger |d 50000 |e 50000PB1032502541 |k 0/50000/ |p 4 | ||
| 998 | |g 129886254 |a Schweizer, Patrick Alexander |m 129886254:Schweizer, Patrick Alexander |d 910000 |d 910100 |e 910000PS129886254 |e 910100PS129886254 |k 0/910000/ |k 1/910000/910100/ |p 3 | ||
| 998 | |g 1055852441 |a Wiedmann, Felix Tobias |m 1055852441:Wiedmann, Felix Tobias |d 50000 |e 50000PW1055852441 |k 0/50000/ |p 2 | ||
| 998 | |g 1055852174 |a Schmidt, Constanze |m 1055852174:Schmidt, Constanze |d 910000 |d 910100 |e 910000PS1055852174 |e 910100PS1055852174 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN176186078X |e 3944797779 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"eki":["176186078X"],"doi":["10.1016/j.ejphar.2013.09.029"]},"language":["eng"],"name":{"displayForm":["Constanze Schmidt, Felix Wiedmann, Patrick A. Schweizer, Rüdiger Becker, Hugo A. Katus, Dierk Thomas"]},"recId":"176186078X","note":["Im Titel ist \"+\" hochgestellt, \"2P\" tiefgestellt","Gesehen am 05.07.2021"],"origin":[{"dateIssuedKey":"2013","dateIssuedDisp":"23 September 2013"}],"physDesc":[{"extent":"12 S."}],"title":[{"title_sort":"Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K+ (K2P) channels","title":"Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K+ (K2P) channels"}],"person":[{"display":"Schmidt, Constanze","given":"Constanze","role":"aut","family":"Schmidt"},{"role":"aut","given":"Felix Tobias","display":"Wiedmann, Felix Tobias","family":"Wiedmann"},{"given":"Patrick Alexander","display":"Schweizer, Patrick Alexander","role":"aut","family":"Schweizer"},{"family":"Becker","role":"aut","given":"Rüdiger","display":"Becker, Rüdiger"},{"role":"aut","given":"Hugo","display":"Katus, Hugo","family":"Katus"},{"family":"Thomas","role":"aut","display":"Thomas, Dierk","given":"Dierk"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"relHost":[{"id":{"eki":["300897340"],"zdb":["1483526-5"],"issn":["1879-0712"]},"language":["eng"],"recId":"300897340","pubHistory":["1.1967 -"],"origin":[{"dateIssuedKey":"1967","publisher":"Elsevier","dateIssuedDisp":"1967-","publisherPlace":"New York, NY [u.a.]"}],"physDesc":[{"extent":"Online-Ressource"}],"disp":"Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K+ (K2P) channelsEuropean journal of pharmacology","part":{"extent":"12","volume":"721","issue":"1/3","pages":"237-248","year":"2013","text":"721(2013), 1/3, Seite 237-248"},"title":[{"title":"European journal of pharmacology","subtitle":"EJP","title_sort":"European journal of pharmacology"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"titleAlt":[{"title":"EJP"}]}],"titleAlt":[{"title":"Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K + (K 2P) channels"},{"title":"Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K plus (K 2P) channels"}]} | ||
| SRT | |a SCHMIDTCONCLASSIANTI2320 | ||